Latest News

Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation

Date: April 3, 2024 | READ MORE >

---

Ampio Announces Voluntary Delisting and SEC Deregistration

Date: March 25, 2024 | READ MORE >

---

Ampio Provides Update on Results from Pre-IND Enabling Studies

Date: February 15, 2024 | READ MORE >

---

Ampio Provides Litigation Update Reports Settlement in Principle of Certain Pending Legal Actions

Date: January 12, 2024 | READ MORE >

---

Ampio CEO, Mike Martino, presents at the Emerging Growth Conference Nov. 2nd

Date: November 20, 2023 | READ MORE >

---

Ampio presents at Emerging Growth Conference November 2nd

Date: November 6, 2023 | READ MORE >

---

Ampio Pharmaceuticals to Present at the Emerging Growth Conference

Date: November 1, 2023 | READ MORE >

---

Ampio CEO, Mike Martino, presents at the Emerging Growth Conference

Date: October 8, 2023 | READ MORE >

---

Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201

Date: October 6, 2023 | READ MORE >

---

Ampio Pharmaceuticals to Present at the Emerging Growth Conference

Date: September 26, 2023 | READ MORE >

---

AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERS

Date: January 19, 2023 | READ MORE >

---

Ampio Pharmaceuticals Issues Letter to Stockholders

Date: October 14, 2022 | READ MORE >

---

Annual Stockholders Meeting

Date: August 9, 2022 | READ MORE >

---

Ampio Letter to Stockholders

Date: August 3, 2022 | READ MORE >

---

Ampio Pharmaceuticals’ CEO Mike Martino Issues Letter to Stockholders

Date: June 2, 2022 | READ MORE >

---